Keynote Speaker
-
Luigi Naldini
San Raffaele Telethon Institute for Gene Therapy and San Raffaele University, Milan, Italy
Luigi Naldini, M.D., Ph.D., is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy (Milan, Italy). He received his medical degree from the University of Turin (Italy) and his PhD from the University “La Sapienza” of Rome (Italy).
For the past 25 years he has pioneered the development and application of lentiviral vectors for gene therapy, which have become one of the most widely used tools in biomedical research and, upon recently entering clinical testing, are providing a long-sought hope of cures for several currently untreatable and otherwise deadly human diseases. Throughout this time, he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, bringing about innovative solutions that are not only being translated into new therapeutic strategies for genetic disease and cancer, but have also yielded novel insights into haematopoietic stem cell function, induction of immunological tolerance, and tumour angiogenesis.
Professor Naldini's work has also contributed to advancing the use of artificial nucleases for targeted genome editing in cell- and gene therapy. To date, he has published over 290 scientific papers, and his SCOPUS Author h-index is 105. He is also co-founder of three innovative biotech start-up companies: Genenta (recently listed on Nasdaq), Epsilen Bio (now acquired by Chroma Medicine) and Genespire.
Confirmed Scientific Speakers
-
Alessia Cavazza
University College London, United Kingdom
Alessia is a Group Leader and Associate Professor in Gene Therapy at University College London's Great Ormond Street Institute of Child Health.
-
Alvin Luk
HuidaGene Therapeutics, Inc.
Alvin Luk is Co-Founder, CEO, and Head of Medical at HuidaGene Therapeutics, Inc.
Alvin will speak at the CRISPRMED24 Virtual Event 22nd April.
-
André Cohnen
Bayer Pharmaceuticals
André is the VP and Head of Genomic Medicine at Bayer Pharmaceuticals.
-
Andrew Bellinger
Verve Therapeutics
Andrew is the Chief Scientific Officer and Founder of Verve Therapeutics, a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. He's also a Co-Founder at Corner Therapeutics.
-
Angelo Lombardo
San Raffaele - Telethon Institute for Gene Therapy, Italy
Angelo is a Group Leader at the San Raffaele - Telethon Institute for Gene Therapy (SR-Tiget) and Professor at the Vita-Salute San Raffaele University in Milano, Italy. He is also a Co-founder of Chroma Medicine.
-
Anna Cereseto
University of Trento, Italy
Anna is a Professor and Vice Director of the Department of Cellular, Computational and Integrative Biology at University of Trento, where she leads the Laboratory of Molecular Virology. She is also co-founder of Alia Therapeutics.
-
Antonio Casini
Alia Therapeutics
Antonio is a Co-Founder and CTO at Alia Therapeutics.
-
Avencia Sánchez-Mejías
Integra Therapeutics
Avencia is the CEO & co-founder at Integra Therapeutics.
-
Ayal Hendel
Bar-Ilan University, Israel.
Ayal is a Principal Investigator at The Mina and Everard Goodman Faculty of Life Sciences at Bar-Ilan University.
-
Ben Kleinstiver
Harvard Medical School and Massachusetts General Hospital
Ben is an Assistant Professor at the Center for Genomic Medicine, at Harvard Medical School, as well as a MGH Research Scholar at Massachusetts General Hospital.
-
Bernhard Schmierer
Karolinska Institutet, Sweden
Bernhard is the head of the CRISPR Functional Genomics unit at the SciLifeLab and Karolinska Institutet in Stockholm, Sweden.
-
Brian Cosgrove
Tune Therapeutics
Brian Cosgrove is a Principal Scientist at Tune Therapeutics and the research lead for the Hepatitis B program.
Brian will speak at the CRISPRMED24 Virtual Event 22nd April.
-
Daniel Schraivogel
EMBL
Research Staff Scientist at EMBL.
LinkedIn Lab Webpage -
Fiona M. Behan
GlaxoSmithKline Pharma
Fiona is the Scientific Director at GlaxoSmithKline Pharma.
-
Jan Gorodkin
University of Copenhagen, Denmark
Jan is a Professor and Group Leader at the University of Copenhagen.
-
Jan Nelis
Ariya Bio
Jan is a Co-Founder and Project Lead at Ariya Bio.
-
Jin Chen
Altos Labs, USA
Jin is a Principal Investigator at Altos Labs and an assistant professor at UT Southwestern Medical Center in Dallas, USA.
-
Jonas Hink
SNIPR Biome
Jonas Hink is the Chief Medical Officer at SNIPR Biome.
-
Julien Valton
Cellectis
Julien is the Vice-President of Gene Therapy at Cellectis.
-
Karim Benabdellah
Fundación Pública Andaluza Progreso y Salud, Spain.
Karim is a Senior Scientist at the GENyO. Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research in Granada, Spain.
Google Scholar ORCIID LinkedIn Edición Genómica aplicada a Terapias Avanzas (eGATA) - Genyo
-
Karina Thorn
Novo Nordisk
Karina is Corporate Vice President, PhD, Head of Research, Global Nucleic Acid Therapies (GNAT) at Novo Nordisk.
Karina has a PhD in Biochemistry from the Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark. After working several years in Boston, US, Karina joined Novo Nordisk in 2014.
Since then, she has successfully been driving research projects, portfolio innovation, and preclinical research areas via scientific, strategic, and people leadership. Furthermore, and as a result of her passion for unlocking therapeutic innovation via emerging technologies, Karina has been instrumental in establishing a broad palette of external Novo Nordisk partnerships and acquisitions.
Karina is a strong and innovative leader who has committed her career to improving the lives of millions of people worldwide living with serious chronic conditions, by unleashing creativity through her collaborative ‘United by Science’ drive and ‘transforming intracellular therapies from the few to the many’ fuel.
-
Laura Sepp-Lorenzino
Laura is the Executive Vice President and Chief Scientific Officer at Intellia Therapeutics.
-
Luigi Naldini
San Raffaele Telethon Institute for Gene Therapy and San Raffaele University, Milan, Italy
Luigi is the Director of the San Raffaele Telethon Institute for Gene Therapy (TIGET) and a Prof. of Histology and Gene and Cell Therapy at the Vita-Salute San Raffaele University in Milan.
-
Manuel Kaulich
Goethe University Frankfurt, Germany
Manuel is a LOEWE-FCI Professor at Goethe University Frankfurt. He is also the Chief Scientific Officer at Vivlion, and the head of the Frankfurt CRISPR Screening Center.
-
Marcello Maresca
AstraZeneca
Marcello is the Senior Director of Genome Engineering at AstraZeneca.
-
Marianne Carlon
Catholic University (KU) Leuven, Belgium
Marianne is an Ass. Prof. at the Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) and the Center for Molecular Medicine of the KU Leuven Faculty of Medicine.
Google Scholar ORCIID LinkedIn BREATHE Webpage KU Leuven Webpage
-
Michael Krohn
Akribion Genomics
Michael Krohn is Co-CEO at Akribion Genomics.
Michael will speak at the CRISPRMED24 Virtual Event 22nd April.
-
Nikhil Gupta
Cancer Research UK
Nikhil is a Principal Scientist at the Joint AstraZeneca-Cancer Research Horizons Functional Genomics Centre, UK.
-
Paula Rio
CIEMAT/CIBERER/IIS-FJD, Universidad Autónoma de Madrid
Paula is the Head of the Bone Marrow Failure Unit at CIEMAT/CIBERER/IIS-FJD at the Universidad Autónoma in Madrid.
-
Pia Johansson
Lund University, Sweden
Pia is the Scientific Coordinator of the Cell and Gene Therapy Core at Lund University.
-
Rasmus O. Bak
Aarhus University, Denmark
Rasmus is a tenured Associate Professor at the Department of Biomedicine at Aarhus University. He is also the co-founder of UNIKUM Therapeutics.
-
Roberto Nitsch
AstraZeneca
Roberto is the Associate Director of Gene Therapy Safety Group at AstraZeneca.
-
Samanta Maragh
National Institute of Standards & Technology, USA
Samantha is the Leader of the Gene Editing Program at the National Institute of Standards & Technology, in the USA.
-
Seung Wook Yang
Amgen
Seung is a Principal Scientist at Amgen.
Google Scholar ORCIID LinkedIn Company Webpage -
Simone Spuler
Charité Universistätsmedizin Berlin / Max Delbrück Center
Simone is a Full Professor at Charité Universistätsmedizin Berlin and a Group Leader at Max Delbrück Center, in Germany.
LinkedIn Google Scholar ORCIID Lab Webpage -
Stefano Stella
Ensoma
Stefano is the Vice-President of Gene Editing at Ensoma, and the Founder and Chief Technology Officer at Twelve Bio. He is also an Ass. Prof. at the Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark.
-
Toni Cathomen
University of Freiburg, Germany
Toni is the Director of the Institute for Transfusion Medicine and Gene Therapy in the University Medical Centre in Freiburg. He is also a Professor of Gene and Cell Therapy at the University of Freiburg.
-
Veronika Jekerle
European Medicines Agency (EMA)
Veronika Jekerle is Head of Pharmaceutical Quality, Human Division, at the European Medicines Agency (EMA), Amsterdam, NL.
Veronika will speak at the CRISPRMED24 Virtual Event 22nd April and be a panelist in the Panel Discussion: Standards and Regulations, 24th April.
-
Xavier Duportet
Eligo Bioscience
Xavier is the co-founder and CEO of Eligo Bioscience. He also co-founded Deeptech Founders and Hello Tomorrow, and is part of the Advisory Boards at Université Paris-Saclay and Universcience.
-
Yonglun Luo
Aarhus University, Denmark
Yonglun is a Professor in Gene and Stem Cell Technology at the Department of Biomedicine at Aarhus University. He is also an Affiliated Researcher at the Steno Diabetes Center in Aarhus, as well as the Executive Director at the Lars Bolund Institute of Regenerative Medicine.
-
Waseem Qasim
UCL Great Ormond Street Institute of Child Health, UK
Waseem is a Consultant in Paediatric Immunology and a Prof. of Cell & Gene Therapy at the Infection, Immunity & Inflammation Department at University College London (UCL) Great Ormond Street (GOS) Institute of Child Health
-
Zhenya Ivakine
The Hospital for Sick Children
Zhenya is a Group Leader at The Hospital for Sick Children in Toronto, Canada.
Sponsored talks by industry speakers
-
Ashley Jacobi
Integrated DNA Technologies
Ashley is the Director of Applications & Market Development at Integrated DNA Technologies.
-
Fan Zhou
GenScript Biotech
Dr. Fan Zhou, PhD, is a senior scientist of molecular biology at GenScript Biotech.
-
Hao Wu
Full Circles Therapeutics/Stellate DNA, USA
Hao is the Co-Founder and CSO of Full Circles Therapeutics, as well as the Director of Stellate DNA.
-
Iván Hernández
Iván is the CSO of Countagen AB.
Iván will speak at the CRISPRMED24 Virtual Event 22nd April.
-
Kevin Holden
Synthego
Kevin is the Head of Science & Applied Research at Synthego. He is also a Scientific Advisor at Minus.
-
Paul Diehl
Cellecta
Paul is the Chief Operating Officer and Director of Business Development at Cellecta.
-
Raoul Hennig
BioSpring
Raoul Hennig, Ph.D. is Head of Manufacturing Site II at BioSpring
-
Sidsel Alsing
Samplix
Sidsel is a Field Application Scientist at Samplix
-
Simon Reed
Broken String Biosciences
Simon is the Co-Founder and CSO at Broken String Biosciences.
-
Vasileios Georgakakos
Clean Cells